Physician
Interventional Pain Center PLLC
Interventional Pain Center PLLC was paid $6.14M by Medicaid between Jan 2018 and Dec 2024, across 55 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 31% of everything it billed.
33Billing provider infoINTERVENTIONAL PAIN CENTER PLLC
FAYETTEVILLE, NC 28304
FAYETTEVILLE, NC 28304
33aNPI1558428789assigned 01/03/2007
33bProvider typePain Medicine (Anesthesiology) Physician
28Total paid$6.14M
24GClaims207,261
24DCodes billed55
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pain Medicine (Anesthesiology) Physician providers in North Carolina
Rank by total paid#2 of 43
Median peer was paid$90K
This provider vs. median68×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TINCH, SHANEKA controls 16+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 42,885 | $1.30M | |
| 2019 | 46,655 | $1.23M | |
| 2020 | 39,674 | $1.17M | |
| 2021 | 32,279 | $922K | |
| 2022 | 20,493 | $732K | |
| 2023 | 14,083 | $474K | |
| 2024incomplete | 11,192 | $317K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 31% | 79,452 | 54,442 | $1.89M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 26% | 53,851 | 36,731 | $1.61M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 13% | 5,934 | 4,563 | $780K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 9.5% | 5,057 | 4,261 | $586K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 6.8% | 8,026 | 6,210 | $420K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 3.5% | 2,174 | 2,033 | $213K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.9% | 2,011 | 1,611 | $114K |
| 80305 | 1.7% | 20,166 | 15,004 | $102K | |
| 64483 | 1.4% | 1,454 | 753 | $87K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.1% | 1,009 | 760 | $67K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 1,683 | 1,116 | $58K |
| 64484 | <1% | 1,227 | 601 | $45K |
43 more codes
| 62323 | <1% | 654 | $35K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 11,977 | $23K |
| 64493 | <1% | 493 | $19K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,883 | $17K |
| 20610 | <1% | 899 | $15K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 458 | $11K |
| 64494 | <1% | 477 | $10K | |
| 64495 | <1% | 416 | $8K | |
| 77002 | <1% | 678 | $8K | |
| 20611 | <1% | 399 | $8K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 840 | $5K |
| 64635 | <1% | 83 | $3K | |
| 64636 | <1% | 81 | $2K | |
| 99442 | <1% | 50 | $623.49 | |
| 20553 | <1% | 47 | $531.58 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,745 | $367.15 |
| 80347 | <1% | 111 | $276.48 | |
| 80323 | <1% | 87 | $223.85 | |
| 83992 | <1% | 87 | $221.87 | |
| 80361 | <1% | 111 | $204.00 | |
| 20552 | <1% | 17 | $196.57 | |
| 80348 | <1% | 111 | $196.32 | |
| 80356 | <1% | 111 | $190.80 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 796 | $172.40 |
| 80365 | <1% | 111 | $170.16 | |
| 80354 | <1% | 87 | $167.75 | |
| 80324 | <1% | 87 | $166.76 | |
| 80358 | <1% | 111 | $157.44 | |
| 80362 | <1% | 87 | $151.80 | |
| 80349 | <1% | 87 | $147.62 | |
| 80373 | <1% | 111 | $147.60 | |
| 80369 | <1% | 87 | $146.85 | |
| 80372 | <1% | 87 | $139.04 | |
| 80367 | <1% | 87 | $137.61 | |
| 80353 | <1% | 87 | $134.20 | |
| 80368 | <1% | 111 | $126.00 | |
| 80360 | <1% | 87 | $119.24 | |
| 80359 | <1% | 87 | $111.32 | |
| 80355 | <1% | 87 | $100.98 | |
| 80366 | <1% | 87 | $90.75 | |
| 80335 | <1% | 87 | $55.00 | |
| 99152 | <1% | 15 | $54.46 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 16 | $2.24 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTINCH, SHANEKA (RCM MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Center for Pain Management, LLC | Hagerstown, MD | $18.80M |
| Physical Medicine Associates, LTD | Mc Lean, VA | $1.79M |
| Asc Development Company, LLC | Hagerstown, MD | $113K |
| Asc Development Company, LLC | Frederick, MD | $42K |
| Asc Development Company, LLC | Germantown, MD | $31K |
| Florida Pain and Rehabilitation Associates INC | Delray Beach, FL | $25K |
| Asc Development Company, LLC | Pikesville, MD | $24K |
| Asc Development Company, LLC | Glen Burnie, MD | $24K |
| Center for Pain Management, LLC | Columbia, MD | $15K |
| Asc Development Company LLC | White Plains, MD | $14K |
| Asc Development Company, LLC | Bel Air, MD | $7K |
| NSPC Surgery Center of Maryland LLC | Oxon Hill, MD | $6K |
| National Surgical Centers of America LLC | Winter Park, FL | $2K |
| Florida Pain and Rehabilitation Associates INC | Delray Beach, FL | $377.09 |
| Physical Medicine Associates LTD | Oxon Hill, MD | $0.00 |
| Pain Consultants Asc LLC | Pascagoula, MS | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.